Citations

Clear

3030 citation(s) found for "Susan, M".

COVID-19 Vaccine Hesitancy Among Deployed Personnel in a Joint Environment
Higginson, Jason, Tumin, Dmitry , Kuehhas, Timothy C, DeLozier-Hooks, Susan E, Powell, Carl A, Ramirez, Dale D, Dabelić, Anja, Basso, Michael R.

Mayo Clinic

Military Medicine | December 13, 2021 | Volume: 188 | Issue: 1-2 | Pages: e32-e36

10.1093/milmed/usab518 | PMID 34897473 Get It

ABSTRACT Introduction In the United States, vaccine hesitancy has been identified as a major barrier to vaccination against COVID-19, but attitudes toward COVID-19 vaccination among military personnel are not well understood. We evaluated the prevalence and correlates of COVID-19 vaccine consent or refusal among deployed personnel in a joint environment. Materials and Methods Deidentified data were retrospectively extracted from the electronic medical record of the Military Health System in May 2021. All personnel currently assigned to the deployment area of operations were included in the analysis if their choice to receive the vaccine was known. Personnel characteristics were compared by vaccine acceptance status using chi-square tests, Fisher’s exact tests, or correlation coefficients. This analysis was exempted from Institutional Review Board review. Results The sample included 1,809 individuals, primarily members of the Army (72%) and members of Reserve (53%) or National Guard (27%) units. In the overall sample, 61% accepted the vaccine, with vaccine acceptance rates being lowest among Black or African American personnel (54%; P = .03 for comparison across racial groups) and members of Reserve or National Guard units (59%; P < .001 for comparison by component). No differences in vaccine acceptance were found according to sex or health status (including prior COVID-19 infection). Conclusions Overall vaccine acceptance was greater among deployed military personnel than that reported in the U.S. population as a whole. However, lower vaccine acceptance among personnel from marginalized populations suggests a need to ensure that all service members have sufficient opportunities to have a frank and ongoing discussion with health care providers to address concerns related to vaccination. Additionally, lower vaccine acceptance among Reserve and National Guard personnel indicates a need for innovative educational approaches to counter vaccine hesitancy in the premobilization phase of deployment.
Validated biomarker assays confirm that ARID1A loss is confounded with MMR deficiency, CD8
Heinze, Karolin , Nazeran, Tayyebeh M., Lee, Sandra , Krämer, Pauline , Leung, Samuel , Kang, Eun Young , Meagher, Nicola S. , Kennedy, Catherine J. , Boros, Jessica , Kommoss, Friedrich, Vollert, Hans‐Walter, Harter, Philipp , Kraemer, Bernhard , Staebler, Annette , Heublein, Sabine , Sinn, Hans‐Peter , Singh, Naveena , Laslavic, Angela , Olawaiye, Alex, Moysich, Kirsten B. , Sharma, Raghwa , Brand, Alison H. , Harnett, Paul R. , DeFazio, Anna , Fortner, Renée T. , Lener, Marcin , Tołoczko‐Grabarek, Aleksandra, Coulson, Penny , El‐Bahrawy, Mona , Jones, Michael E. , Schoemaker, Minouk J. , Gayther, Simon A. , Carney, Michael E. , Shvetsov, Yurii B. , Hernandez, Brenda Y. , Goodman, Marc T. , Mateoiu, Constantina , Linder, Anna , Kelemen, Linda E. , Widschwendter, Martin , Menon, Usha , Alsop, Jennifer , Shah, Mitul , Jimenez‐Liñan, Mercedes , Brenton, James D. , Cushing‐Haugen, Kara L. , Huntsman, David G. , Nelson, Gregg , Tinker, Anna V. , Goode, Ellen L. , Ramus, Susan J. , Kommoss, Stefan , Talhouk, Aline , Köbel, Martin , Anglesio, Michael S. , Campbell, Ian G , Gilks, C. Blake , Köbel, Martin , Anglesio, Michael S , Fazio, Anna de , Fortner, Renée T , Ramus, Susan J , Menon, Usha , Brenton, James D , Moysich, Kirsten , Kennedy, Catherine J , Sinn, Peter , Widschwendter, Martin , Jones, Michael E , Brand, Alison H , Nelson, Gregg S , El-Bahrawy, Mona A , Harnett, Paul R , Hernandez, Brenda Y , Schoemaker, Minouk J , Goodman, Marc T , Linder, Anna , Cairns, Evan S. , Chiu, Derek S , Heitz, Florian , Bois, Andreas du , Grube, Marcel , Kommoss, Felix , Elishaev, Esther , Modugno, Francesmary , Lubiński, Jan , Cybulski, Cezary , Gronwald, Helena , Gronwald, Jacek , Swerdlow, Anthony J. , Gorringe, Kylie L. , Campbell, Ian , Cook, Linda S. , Wilkens, Lynne R. , Sundfeldt, Karin , Gentry‐Maharaj, Aleksandra , Bolton, Kelly L. , Pharoah, Paul D.P. , Harris, Holly R. , Doherty, Jennifer A. , Ghatage, Prafull , Lee, Cheng‐Han , Nelson, Brad H.

Mayo Clinic

The Journal of Pathology | December 13, 2021 | Volume: 256 | Issue: 4 | Pages: 388-401

10.1002/path.5849 | PMID 34897700 Get It

Abstract ARID1A (BAF250a) is a component of the SWI/SNF chromatin modifying complex, plays an important tumour suppressor role, and is considered prognostic in several malignancies. However, in ovarian carcinomas there are contradictory reports on its relationship to outcome, immune response, and correlation with clinicopathological features. We assembled a series of 1623 endometriosis‐associated ovarian carcinomas, including 1078 endometrioid (ENOC) and 545 clear cell (CCOC) ovarian carcinomas, through combining resources of the Ovarian Tumor Tissue Analysis (OTTA) Consortium, the Canadian Ovarian Unified Experimental Resource (COEUR), local, and collaborative networks. Validated immunohistochemical surrogate assays for ARID1A mutations were applied to all samples. We investigated associations between ARID1A loss/mutation, clinical features, outcome, CD8 + tumour‐infiltrating lymphocytes (CD8 + TILs), and DNA mismatch repair deficiency (MMRd). ARID1A loss was observed in 42% of CCOCs and 25% of ENOCs. We found no associations between ARID1A loss and outcomes, stage, age, or CD8 + TIL status in CCOC. Similarly, we found no association with outcome or stage in endometrioid cases. In ENOC, ARID1A loss was more prevalent in younger patients ( p = 0.012) and was associated with MMRd ( p < 0.001) and the presence of CD8 + TILs ( p = 0.008). Consistent with MMRd being causative of ARID1A mutations, in a subset of ENOCs we also observed an association with ARID1A loss‐of‐function mutation as a result of small indels ( p = 0.035, versus single nucleotide variants). In ENOC, the association with ARID1A loss, CD8 + TILs, and age appears confounded by MMRd status. Although this observation does not explicitly rule out a role for ARID1A influence on CD8 + TIL infiltration in ENOC, given current knowledge regarding MMRd, it seems more likely that effects are dominated by the hypermutation phenotype. This large dataset with consistently applied biomarker assessment now provides a benchmark for the prevalence of ARID1A loss‐of‐function mutations in endometriosis‐associated ovarian cancers and brings clarity to the prognostic significance. © 2021 The Pathological Society of Great Britain and Ireland.
Accelerated Idioventricular Rhythm: A Benign Arrhythmia in Childhood
MacLellan-Tobert, Susan G., Porter, Co-burn J.

Mayo Clinic

Pediatrics | December 11, 2021 | Volume: 96 | Issue: 1 | Pages: 122-125

10.1542/peds.96.1.122 Get It

Objective. To determine whether accelerated idioventricular rhythm (AIVR) is benign in pediatric patients. Methods. The records were reviewed of all patients younger than age 15 years who had been diagnosed with a ventricular arrhythmia between 1976 and 1991. Results. AIVR was diagnosed in 12 patients, ages 1 day to 15 years (mean, 8.9 years). In 3 patients the arrhythmia was discovered on ambulatory electrocardiographic monitoring after presentation with syncope or presyncopal symptoms. One patient had palpitations. The remaining diagnoses were made during routine examinations or at postoperative follow-ups for congenital heart disease. The AIVR rate ranged from 90 to 150 beats per minute. The rate was within 10 beats per minute of the preceding sinus rate in 11 patients. Echocardiograms were normal in 8 patients. Two patients had double-outlet right ventricles; 1 had repair of the tetralogy of Fallot; and 1 had abnormal ventricular septal motion. Seven patients were taking antiarrhythmia medication without control of the AIVR at presentation. Patients were followed for a mean of 68.4 months (range, 31 to 191 months). All patients were alive and asymptomatic, with normal activity at the last follow-ups. Conclusions. Complete resolution of AIVR may not occur. However, AIVR seems to be a benign arrhythmia. Treatment was not effective in controlling the arrhythmia and is likely unnecessary.
Metabolic Aspects of Myocardial Disease and a Role forl-Carnitine in the Treatment of Childhood Cardiomyopathy
Helton, Edward D., Darragh, Robert K. , Francis, Paul, Fricker, Frederick J., Jue, Kenneth L., Koch, Gary G., Mair, Douglas D., Pierpont, Mary Ella , Procházka, J, Linn, Lawrence S., Winter, Susan, Prochazka, James V., Linn, Lawrence S.

Mayo Clinic

Pediatrics | December 10, 2021 | Volume: 105 | Issue: 6 | Pages: 1260-1270

10.1542/peds.105.6.1260 Get It

Objectives.A multicenter retrospective study was conducted to investigate the possible metabolic causes of pediatric cardiomyopathy and evaluate the outcome of patients treated with l-carnitine.Methods.Seventy-six patients diagnosed with cardiomyopathy were treated with l-carnitine in addition to conventional cardiac treatment, and 145 patients were treated with conventional treatment only. There were 101 males and 120 females between 1 day and 18 years old. Cardiomyopathy diagnoses included dilated (148 patients), hypertrophic (42 patients), restrictive (16 patients), mixed diagnosis (11 patients), and 4 with an unknown type. Of 76 l-carnitine-treated patients, 29 (38%) had evidence to suggest a disorder of metabolism, and of 145 control patients, 15 (10%) were suspected to have a disorder of metabolism. These metabolic disorders were thought to be the cause for the cardiomyopathy of the patients. The duration of l-carnitine treatment ranged from 2 weeks to &gt;1 year. Information was collected on length of survival (time-to-event), clinical outcome, echocardiogram parameters, and clinical assessments. Data were collected at intervals from baseline to study endpoint, death, transplant, or last known follow-up visit.Results.l-Carnitine-treated patients were younger than control patients and had poorer clinical functioning at baseline, yet they demonstrated lower mortality and a level of clinical functioning and clinical severity comparable to control patients on conventional therapy by the end of the study. An analysis of the interaction between clinical outcome and concomitant medications unexpectedly revealed that the population of patients treated with angiotensin-converting enzyme (ACE) inhibitors (40% of patients) had significantly poorer survival (although their greater likelihood for poor survival may possibly have made them more likely to receive ACE inhibitors).Conclusion.Results suggest that l-carnitine provides clinical benefit in treating pediatric cardiomyopathy. There is a need for further exploration of potential explanatory factors for the higher mortality observed in the population of patients treated with ACE inhibitors.
Tilt-Table Testing and Oral Metoprolol Therapy in Young Patients With Unexplained Syncope
MacLellan-Tobert, Susan C., Porter, Co-burn J., O’Marcaigh, Aengus

Mayo Clinic

Pediatrics | December 9, 2021 | Volume: 93 | Issue: 2 | Pages: 278-283

10.1542/peds.93.2.278 Get It

Objective. Tilt-table testing is useful for investigating unexplained syncope in pediatric patients. No data are available on the use of intravenous metoprolol during testing to identify children who might respond to subsequent oral β-adrenergic blockade or on the efficacy and safety of such oral therapy. Design. To provide these data, we obtained follow-up information on 27 consecutive pediatric patients who had tilt-table testing for unexplained syncope. Results. Nineteen patients (70%) had positive test results with or without isoproterenol infusion. All these patients had negative test results after intravenous infusion of metoprolol and subsequently were treated with oral metoprolol. Taking oral metoprolol therapy alone, 9 (47%) of the 19 patients were asymptomatic, 8 (42%) reported a decreased frequency of syncopal episodes, and 2 (11%) had unchanged or more frequent episodes. The mean dosage of metoprolol required to prevent symptoms was 1.5 mg/kg per day. Mild side effects were reported by 6 (32%) of the 19 patients. Six patients (32%) required additional medications. Conclusions. We conclude that metoprolol is safe and effective for the treatment of most cases of neurocardiogenic syncope in children and that this response cannot be predicted accurately by the use of intravenous metoprolol during testing.
Recommendations From the Society for the Advancement of Transplant Anesthesiology Fellowship Committee: Core Competencies and Milestones for the Kidney/Pancreas Component of Abdominal Organ Transplant Anesthesia Fellowship
Souki, Fouad G. , Chadha, Ryan , Planinsic, Raymond M. , Zerillo, Jeron , Nguyen, Christine , Smith, Natalie , Mandell, M. Susan , Sakai, Tetsuro , Nicolau‐Raducu, Ramona , Chadha, Ryan , Nguyen-Buckley, Christine

Mayo Clinic

Seminars in Cardiothoracic and Vascular Anesthesia | December 7, 2021 | Volume: 26 | Issue: 1 | Pages: 15-26

10.1177/10892532211058574 | PMID 34872395 Get It

The Society for the Advancement of Transplant Anesthesia (SATA) is dedicated to improving patient care in all facets of transplant anesthesia. The anesthesia fellowship training recommendations for thoracic transplantation (heart and lungs) and part of the abdominal organ transplantation (liver) have been presented in previous publications. The SATA Fellowship Committee has completed the remaining component of abdominal transplant anesthesia (kidney/pancreas) and has assembled core competencies and milestones derived from expert consensus to guide the education and overall preparation of trainees providing care for kidney/pancreas transplant recipients. These recommendations provide a comprehensive approach to pre-operative evaluation, vascular access procedures, advanced hemodynamic monitoring, assessment of coagulation and metabolic abnormalities, operative techniques, and post-operative pain control. As such, this document supplements the current liver/hepatic transplant anesthesia fellowship training programs to include all aspects of “Abdominal Organ Transplant Anesthesia” recommended knowledge.
REcognizing DElirium in geriatric Emergency Medicine: The REDEEM risk stratification score
Silva, Lucas Oliveira J. e , Stanich, Jessica A. , Jeffery, Molly M. , Mullan, Aidan F. , Bower, Susan M. , Campbell, Ronna L. , Rabinstein, Alejandro A. , Pignolo, Robert J. , Bellolio, Fernanda , Oliveira J E Silva, Lucas , Jeffery, Molly Moore , Bellolio, M Fernanda , Campbell, Ronna L , Rabinstein, Alejandro A , Mullan, Aidan , Bower, Susan M.

Mayo Clinic

Academic Emergency Medicine | December 6, 2021 | Volume: 29 | Issue: 4 | Pages: 476-485

10.1111/acem.14423 | PMID 34870884 Get It

Abstract Objective The objective was to derive a risk score that uses variables available early during the emergency department (ED) encounter to identify high‐risk geriatric patients who may benefit from delirium screening. Methods This was an observational study of older adults age ≥ 75 years who presented to an academic ED and who were screened for delirium during their ED visit. Variable selection from candidate predictors was performed through a LASSO‐penalized logistic regression. A risk score was derived from the final prediction model, and predictive accuracy characteristics were calculated with 95% confidence intervals (CIs). Results From the 967 eligible ED visits, delirium was detected in 107 (11.1%). The area under the curve for the REcognizing DElirium in Emergency Medicine (REDEEM) score was 0.901 (95% CI = 0.864–0.938). The REEDEM risk score included 10 different variables (seven based on triage information and three obtained during early history taking) with a score ranging from –3 to 66. Using an optimal cutoff of ≥11, we found a sensitivity of 84.1% (90 of 107 ED delirium patients, 95% CI = 75.5%–90.2%) and a specificity of 86.6% (745 of 860 non‐ED delirium patients, 95% CI = 84.1%–88.8%). A lower cutoff of ≥5 was found to minimize false negatives with an improved sensitivity at 91.6% (98 of 107 ED delirium patients, 95% CI = 84.2%–95.8%). Conclusion A risk stratification score was derived with the potential to augment delirium recognition in geriatric ED patients. This has the potential to assist on delirium‐targeted screening of high‐risk patients in the ED. Validation of REDEEM, however, is needed prior to implementation.
The use of nondirected donor organs in living donor liver transplantation: Perspectives and guidance
Fox, Alyson N. , Liapakis, AnnMarie , Batra, Ramesh , Bittermann, Therese , Emamaullee, Juliet , Emre, Sukru , Genyk, Yuri , Han, Hyosun , Jackson, Whitney E. , Rodríguez-Dávalos, Manuel I. , Gold, Susan Rubman, Shenoy, Akhil , Taner, Timuçin , (NALLDIG), The North American Living Liver Donor Innovations Group, Taner, Timucin , Pomfret, Elizabeth , Raza, Muhammad, Samstein, Benjamin , Roberts, John P. , (NALLDIG), The North American Living Liver Donor Innovations Group

Mayo Clinic

Hepatology | December 3, 2021 | Volume: 75 | Issue: 6 | Pages: 1579-1589

10.1002/hep.32260 | PMID 34859474 Get It

Abstract Interest in anonymous nondirected living organ donation is increasing in the United States and a small number of transplantation centers are accumulating an experience regarding nondirected donation in living donor liver transplantation. Herein, we review current transplant policy, discuss emerging data, draw parallels from nondirected kidney donation, and examine relevant considerations in nondirected living liver donation. We aim to provide a consensus guidance to ensure safe evaluation and selection of nondirected living liver donors and a schema for just allocation of nondirected grafts.
Socioeconomic and demographic factors in the diagnosis and treatment of Chiari malformation type I and syringomyelia
Akbari, Syed Hassan A., Rizvi, Asad A., CreveCoeur, Travis S., Han, Rowland H., Greenberg, Jacob K., Torner, James, Brockmeyer, Douglas L., Wellons, John C., Leonard, Jeffrey R., Mangano, Francesco T., Johnston, James M., Shah, Manish N., Iskandar, Bermans J., Ahmed, Raheel, Tuite, Gerald F., Kaufman, Bruce A., Daniels, David J., Jackson, Eric M., Grant, Gerald A., Powers, Alexander K., Couture, Daniel E., Adelson, P. David, Alden, Tord D., Aldana, Philipp R., Anderson, Richard C. E., Selden, Nathan R., Bierbrauer, Karin, Boydston, William, Chern, Joshua J., Whitehead, William E., Dauser, Robert C., Ellenbogen, Richard G., Ojemann, Jeffrey G., Fuchs, Herbert E., Guillaume, Daniel J., Hankinson, Todd C., O’Neill, Brent R., Iantosca, Mark, Oakes, W. Jerry, Keating, Robert F., Klimo, Paul, Muhlbauer, Michael S., McComb, J. Gordon, Menezes, Arnold H., Khan, Nickalus R., Niazi, Toba N., Ragheb, John, Shannon, Chevis N., Smith, Jodi L., Ackerman, Laurie L., Jea, Andrew H., Maher, Cormac O., Narayan, Prithvi, Albert, Gregory W., Stone, Scellig S. D., Baird, Lissa C., Gross, Naina L., Durham, Susan R., Greene, Stephanie, McKinstry, Robert C., Shimony, Joshua S., Strahle, Jennifer M., Smyth, Matthew D., Dacey, Ralph G., Park, Tae Sung, Limbrick, David D., Torner, James C. , Greene, Stephanie , Jackson, Eric M. , Stone, Scellig , Akbari, Syed Hassan A., Rizvi, Asad A., CreveCoeur, Travis S., Han, Rowland H., Greenberg, Jacob K., Brockmeyer, Douglas L., Wellons, John C., Leonard, Jeffrey R., Mangano, Francesco T., Johnston, James M., Shah, Manish N., Iskandar, Bermans J., Ahmed, Raheel, Tuite, Gerald F., Kaufman, Bruce A., Daniels, David J., Jackson, Eric M., Grant, Gerald A., Powers, Alexander K., Couture, Daniel E., Adelson, P. David, Alden, Tord D., Aldana, Philipp R., Anderson, Richard C. E., Selden, Nathan R., Bierbrauer, Karin, Boydston, William, Chern, Joshua J., Whitehead, William E., Dauser, Robert C., Ellenbogen, Richard G., Ojemann, Jeffrey G., Fuchs, Herbert E., Guillaume, Daniel J., Hankinson, Todd C., O’Neill, Brent R., Iantosca, Mark, Oakes, W. Jerry, Keating, Robert F., Klimo, Paul, Muhlbauer, Michael S., McComb, J. Gordon, Menezes, Arnold H., Khan, Nickalus R., Niazi, Toba N., Ragheb, John, Shannon, Chevis N., Smith, Jodi L., Ackerman, Laurie L., Jea, Andrew H., Maher, Cormac O., Narayan, Prithvi, Albert, Gregory W., Stone, Scellig S. D., Baird, Lissa C., Gross, Naina L., Durham, Susan R., Greene, Stephanie, McKinstry, Robert C., Shimony, Joshua S., Strahle, Jennifer M., Smyth, Matthew D., Dacey, Ralph G., Park, Tae Sung, Limbrick, David D.

Mayo Clinic

Journal of Neurosurgery: Pediatrics | December 3, 2021 | Volume: 29 | Issue: 3 | Pages: 288-297

10.3171/2021.9.peds2185 | PMID 34861643 Get It

OBJECTIVE The goal of this study was to assess the social determinants that influence access and outcomes for pediatric neurosurgical care for patients with Chiari malformation type I (CM-I) and syringomyelia (SM). METHODS The authors used retro- and prospective components of the Park-Reeves Syringomyelia Research Consortium database to identify pediatric patients with CM-I and SM who received surgical treatment and had at least 1 year of follow-up data. Race, ethnicity, and insurance status were used as comparators for preoperative, treatment, and postoperative characteristics and outcomes. RESULTS A total of 637 patients met inclusion criteria, and race or ethnicity data were available for 603 (94.7%) patients. A total of 463 (76.8%) were non-Hispanic White (NHW) and 140 (23.2%) were non-White. The non-White patients were older at diagnosis (p = 0.002) and were more likely to have an individualized education plan (p < 0.01). More non-White than NHW patients presented with cerebellar and cranial nerve deficits (i.e., gait ataxia [p = 0.028], nystagmus [p = 0.002], dysconjugate gaze [p = 0.03], hearing loss [p = 0.003], gait instability [p = 0.003], tremor [p = 0.021], or dysmetria [p < 0.001]). Non-White patients had higher rates of skull malformation (p = 0.004), platybasia (p = 0.002), and basilar invagination (p = 0.036). Non-White patients were more likely to be treated at low-volume centers than at high-volume centers (38.7% vs 15.2%; p < 0.01). Non-White patients were older at the time of surgery (p = 0.001) and had longer operative times (p < 0.001), higher estimated blood loss (p < 0.001), and a longer hospital stay (p = 0.04). There were no major group differences in terms of treatments performed or complications. The majority of subjects used private insurance (440, 71.5%), whereas 175 (28.5%) were using Medicaid or self-pay. Private insurance was used in 42.2% of non-White patients compared to 79.8% of NHW patients (p < 0.01). There were no major differences in presentation, treatment, or outcome between insurance groups. In multivariate modeling, non-White patients were more likely to present at an older age after controlling for sex and insurance status (p < 0.01). Non-White and male patients had a longer duration of symptoms before reaching diagnosis (p = 0.033 and 0.004, respectively). CONCLUSIONS Socioeconomic and demographic factors appear to influence the presentation and management of patients with CM-I and SM. Race is associated with age and timing of diagnosis as well as operating room time, estimated blood loss, and length of hospital stay. This exploration of socioeconomic and demographic barriers to care will be useful in understanding how to improve access to pediatric neurosurgical care for patients with CM-I and SM.
Index60 Identifies Individuals at Appreciable Risk for Stage 3 Among an Autoantibody-Positive Population With Normal 2-Hour Glucose Levels: Implications for Current Staging Criteria of Type 1 Diabetes
Nathan, Brandon M. , Jacobsen, Laura M. , Sims, Emily K. , Palmer, Jerry P., Bocchino, Laura E., Geyer, Susan, Sosenko, Jay M. , Redondo, María J. , Ismail, Heba M. , Skyler, Jay S.

Mayo Clinic

Diabetes Care | December 1, 2021 | Volume: 45 | Issue: 2 | Pages: 311-318

10.2337/dc21-0944 | PMID 34853027 Get It

OBJECTIVE We assessed whether Index60, a composite measure of fasting C-peptide, 60-min C-peptide, and 60-min glucose, could improve the metabolic staging of type 1 diabetes for progression to clinical disease (stage 3) among autoantibody-positive (Ab+) individuals with normal 2-h glucose values (&lt;140 mg/dL). RESEARCH DESIGN AND METHODS We analyzed 3,058 Type 1 Diabetes TrialNet Pathway to Prevention participants with 2-h glucose &lt;140 mg/dL and Index60 &lt;1.00 values from baseline oral glucose tolerance tests. Characteristics associated with type 1 diabetes (younger age, greater Ab+, higher HLA DR3-DQ2/DR4-DQ8 prevalence, and lower C-peptide) were compared among four mutually exclusive groups: top 2-h glucose quartile only (HI-2HGLU), top Index60 quartile only (HI-IND60), both top quartiles (HI-BOTH), and neither top quartile (LO-BOTH). Additionally, within the 2-h glucose distribution of &lt;140 mg/dL and separately within the Index60 &lt;1.00 distribution, comparisons were made between those above or below the medians. RESULTS HI-IND60 and HI-BOTH were younger, with greater frequency of more than two Ab+, and lower C-peptide levels, than either HI-2HGLU or LO-BOTH (all P &lt; 0.001). The cumulative incidence for stage 3 was greater for HI-IND60 and HI-BOTH than for either HI-2HGLU or LO-BOTH (all P &lt; 0.001). Those with Index60 values above the median were younger and had higher frequency of two or more Ab+ (P &lt; 0.001) and DR3-DQ2/DR4-DQ8 prevalence (P &lt; 0.001) and lower area under the curve (AUC) C-peptide levels (P &lt; 0.001) than those below. Those above the 2-h glucose median had higher AUC C-peptide levels (P &lt; 0.001), but otherwise did not differ from those below. CONCLUSIONS Index60 identifies individuals with characteristics of type 1 diabetes at appreciable risk for progression who would otherwise be missed by 2-h glucose staging criteria.